ABOUT US

OUR MISSION

We will accelerate the development of cures through the power of collaboration so children with cancer can grow up to realize their full potential.

Kids First.

We put the health and wellbeing of children ahead of personal acclaim or institutional gain. The success of our work will be measured in healthy children.

 

Stronger Together.

We believe in the power of collaboration and trust that, together with our partners, we will go farther, faster in developing cures. We will put aside individual egos to achieve our common goals.

Constant Innovation.

We will challenge boundaries and be creative in pursuit of our mission. We are unconstrained by the status quo and prioritize the possibility of new discoveries that lead to new cures.

OUR VALUES

OUR LEADERSHIP TEAM

We have assembled a team of experts in the field of CAR T-cell science who are united behind our mission and values. We understand the importance of asking the big questions, the power of a common purpose, and the wonder of human potential.

Michael Jensen, MD
Executive Director

Dr. Jensen is an internationally recognized leader in the field of CAR T-cell immunotherapy with over 20-years’ experience in the research and clinical translation of this therapeutic modality.

READ MORE

Russ Lea, PhD
Deputy Director

Dr. Lea brings over 25-years’ experience in research and development, operations, intellectual property management, and business development roles.

READ MORE

Rimas Orentas, PhD
Director of Scientific Integration

Dr. Orentas received his PhD from the Department of Pharmacology and Molecular Sciences of The Johns Hopkins University School of Medicine.

READ MORE

OUR MEMBERS

Our members are nationally recognized academic children’s hospitals who believe in the power of collaboration. Together, we will expand these innovative therapies to children in our communities, while redefining the state of care globally.

For information about clinical trials in your area, please contact your child’s physician or visit clinicaltrials.gov

CureWorks™ is a trademark of Seattle Children’s
Healthcare System and its related and controlled organizations.
Copyright © 2018 Seattle Children’s Healthcare System.

Michael Jensen, MD
Executive Director

Dr. Jensen is an internationally recognized leader in the field of CAR T-cell immunotherapy with over 20-years’ experience in the research and clinical translation of this therapeutic modality. He has focused the application of his work to childhood cancers. Dr. Jensen graduated from the University of Pennsylvania School of Medicine and then completed training in Pediatric Hematology and Oncology at the University of Washington(UW)/Fred Hutchinson Cancer Research Center (FHCRC) with a focus on the immunobiology of tumor-specific T-cells. After completing his fellowship at FHCRC, he joined the faculty at California’s City of Hope National Medical Center where he built a translational research program integrating gene therapy and cellular immunotherapy for cancer. Dr. Jensen is the founding Director of the Ben Towne Center for Childhood Cancer at Seattle Children’s Research Institute where he continues to pursue a pipeline of cures that treat childhood cancer with the goal of reducing the long-term, debilitating side effects of traditional treatments. As the founding Executive Director of CureWorks, Dr. Jensen is committed to accelerating the progress of immunotherapies for childhood cancers and expanding the access to these therapies for children around the world.

Academic Affiliations

Janet & Jim Sinegal Endowed Chair and Professor, Division of Pediatric Hematology-Oncology, Department of Pediatrics

University of Washington School of Medicine

Joint Member, Fred Hutchinson Cancer Research Center

Adjunct Professor, Department of Bioengineering,

UW School of Medicine

 

 

Russ Lea, PhD
Deputy Director

Dr. Lea brings over 25 years’ experience in research and development, operations, intellectual property management, and business development roles within the educational, health care, environmental, and private sectors. He has proven expertise in sourcing, creating, and maximizing revenue through the utilization of strategic partnerships and innovative programs. His track record of converting complex issues to fundamentals, creating blueprints for action, and implementing systems that guarantee measurable results are key skills that make Dr. Lea uniquely qualified to develop the CureWorks effort, creating a replicable model for future immuno-oncological translational research in investigational drug development.

 

 

Rimas Orentas, PhD
Director of Scientific Integration

Dr. Orentas received his PhD from the Department of Pharmacology and Molecular Sciences of The Johns Hopkins University School of Medicine. While there he held post-doctoral and Research Associate positions in the Oncology Center, followed by a 12-year academic career at the Medical College of Wisconsin, where he rose to rank of Associate Professor with a primary appointment in the Department of Pediatrics, Section of Hematology-Oncology. He also held appointments in the Department of Medicine and the Department of Microbiology and Molecular Genetics.

Dr. Orentas has extensive experience in CAR T-based immunotherapy approaches to cancer therapy, and in addition to his role at CureWorks, he is a Principal Investigator in the Immunology Integration Hub of the Seattle Children’s Research Institute. Prior to his role at CureWorks, he was Scientific Director of Lentigen Technology, Inc., a Miltenyi Biotec company, and served as an Associate Scientist in the Pediatric Oncology Branch of the National Cancer Institute.

 

 

OUR MEMBERS

Our members are nationally recognized academic children’s hospitals who believe in the power of collaboration. Together, we will expand these innovative therapies to children in our communities, while redefining the state of care globally.

 

READ MORE

READ MORE

READ MORE

 

READ MORE

 

ABOUT US

OUR MISSION

We will accelerate the development of cures through the power of collaboration so children with cancer can grow up to realize their full potential.

 

 

 

OUR VALUES

Kids First.

We put the health and wellbeing of children ahead of personal acclaim or institutional gain. The success of our work will be measured in healthy children.

Stronger Together.

We believe in the power of collaboration and trust that, together with our partners, we will go farther, faster in developing cures. We will put aside individual egos to achieve our common goals.

Constant Innovation.

We will challenge boundaries and be creative in pursuit of our mission. We are unconstrained by the status quo and prioritize the possibility of new discoveries that lead to new cures.

 

 

OUR LEADERSHIP TEAM

We have assembled a team of experts in the field of CAR T-cell science who are united behind our mission and values. We understand the importance of asking the big questions, the power of a common purpose, and the wonder of human potential.

 

 

Michael Jensen, MD
Executive Director

Dr. Jensen is an internationally recognized leader in the field of CAR T-cell immunotherapy with over 20-years’ experience in the research and clinical translation of this therapeutic modality. He has focused the application of his work to childhood cancers. Dr. Jensen graduated from the University of Pennsylvania School of Medicine and then completed training in Pediatric Hematology and Oncology at the University of Washington(UW)/Fred Hutchinson Cancer Research Center (FHCRC) with a focus on the immunobiology of tumor-specific T-cells. After completing his fellowship at FHCRC, he joined the faculty at California’s City of Hope National Medical Center where he built a translational research program integrating gene therapy and cellular immunotherapy for cancer. Dr. Jensen is the founding Director of the Ben Towne Center for Childhood Cancer at Seattle Children’s Research Institute where he continues to pursue a pipeline of cures that treat childhood cancer with the goal of reducing the long-term, debilitating side effects of traditional treatments. As the founding Executive Director of CureWorks, Dr. Jensen is committed to accelerating the progress of immunotherapies for childhood cancers and expanding the access to these therapies for children around the world.

Academic Affiliations

Janet & Jim Sinegal Endowed Chair and Professor, Division of Pediatric Hematology-Oncology, Department of Pediatrics

University of Washington School of Medicine

Joint Member, Fred Hutchinson Cancer Research Center

Adjunct Professor, Department of Bioengineering,

UW School of Medicine

 

 

Russ Lea, PhD
Deputy Director

Dr. Lea brings over 25-years’ experience in research and development, operations, intellectual property management, and business development roles within the educational, health care, environmental, and private sectors. He has proven expertise in sourcing, creating, and maximizing revenue through the utilization of strategic partnerships and innovative programs. His track record of converting complex issues to fundamentals, creating blueprints for action, and implementing systems that guarantee measurable results are key skills that make Dr. Lea uniquely qualified to develop the CureWorks effort, creating a replicable model for future immuno-oncological translational research in investigational drug development.

 

 

Rimas Orentas, PhD
Director of Scientific Integration

Dr. Orentas received his PhD from the Department of Pharmacology and Molecular Sciences of The Johns Hopkins University School of Medicine. While there he held post-doctoral and Research Associate positions in the Oncology Center, followed by a 12-year academic career at the Medical College of Wisconsin, where he rose to rank of Associate Professor with a primary appointment in the Department of Pediatrics, Section of Hematology-Oncology. He also held appointments in the Department of Medicine and the Department of Microbiology and Molecular Genetics.

Dr. Orentas has extensive experience in CAR T-based immunotherapy approaches to cancer therapy, and in addition to his role at CureWorks, he is a Principal Investigator in the Immunology Integration Hub of the Seattle Children’s Research Institute. Prior to his role at CureWorks, he was Scientific Director of Lentigen Technology, Inc., a Miltenyi Biotec company, and served as an Associate Scientist in the Pediatric Oncology Branch of the National Cancer Institute.

 

 

OUR MEMBERS

Our members are nationally recognized academic children’s hospitals who believe in the power of collaboration. Together, we will expand these innovative therapies to children in our communities, while redefining the state of care globally.

 

READ MORE

 

READ MORE

 

READ MORE

 

 

 

READ MORE

 

 

For information about clinical trials in your area, please contact your child’s physician or visit clinicaltrials.gov

CureWorks™ is a trademark of Seattle Children’s Healthcare System and its related and controlled organizations.
Copyright © 2018 Seattle Children’s Healthcare System.

CureWorks logo A new way to better cures

CureWorks logo A new way to better cures

CureWorks logo A new way to better cures

CureWorks™ is a trademark of Seattle Children’s Healthcare System and its related and controlled organizations.
Copyright © 2018 Seattle Children’s Healthcare System.